#RSLS

Clinical-Stage Vyome Targets $100B Inflammation Market Through Nasdaq Merger with ReShape Biotech merger creates new entity focused on immuno-inflammatory diseases, trading as HIND. Harvard-linked leadership eyes US-India innovation synergy. Learn merger details.

7 months ago

#RSLS Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

www.stocktitan.net/news/RSLS/vyome-announce...

0 0 0 0

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics ReShape Lifesciences (Nasdaq: RSLS) announced that shareholders have approved the merger with Vyome Therapeutics. The merger is set to become effective on August 15, 2025, coinciding with India's Independence Day. The combined company will be renamed to Vyome Holdings, Inc. and will trade under the new symbol "HIND" on the Nasdaq Capital Market.The transaction includes the sale of ReShape's assets to Biorad Medisys. Vyome aims to establish a healthcare platform focusing on the US-India innovation corridor. Maxim Group LLC and Chardan are serving as financial advisors for ReShape and Vyome respectively, with Fox Rothschild LLP and Sichenzia Ross Ference Carmel LLP acting as legal counsel.

7 months ago

#RSLS ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders ReShape Lifesciences (Nasdaq: RSLS) announced a partial adjournment of its Special Meeting of Stockholders specifically for two critical proposals. The meeting will reconvene on August 7, 2025 to vote on Proposal 2 (Asset Sale Proposal) and Proposal 3 (Charter Amendment Proposal).The Asset Sale Proposal involves the sale of substantially all ReShape's assets to Ninjour Health International Limited, while the Charter Amendment Proposal relates to amendments needed for the proposed merger with Vyome Therapeutics. Both proposals are essential conditions for completing the merger. All other merger-related proposals were successfully approved by stockholders.The company urges all stockholders of record as of June 9, 2025 to vote in favor of these proposals, emphasizing their importance for maximizing stockholder value through the merger completion.

7 months ago

#RSLS ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System ReShape Lifesciences (Nasdaq: RSLS) announced the upcoming issuance of U.S. Patent 12,350,179 by the USPTO on July 8, 2025, covering their intragastric balloon system. The patent specifically protects a swallowable capsule design featuring a self-sealing fill valve and degradable release valve that deflates after three months for natural excretion.The patent will provide protection until at least January 2031, with potential for extension. CEO Paul F. Hickey highlighted that the company has built a substantial intellectual property portfolio, including over 50 patents specifically for their intragastric balloon technology and a total of over 160 issued and pending patents across various proprietary technologies.

8 months ago

#RSLS ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys ReShape Lifesciences (NASDAQ:RSLS) announced strategic cost reductions and updates on pending transactions. The company is implementing a workforce reduction expected to save over $750,000 annually, representing 23.4% of payroll expenses, while maintaining its sales and marketing team intact.The company is progressing with its merger agreement with Vyome Therapeutics and an asset purchase agreement with Biorad Medisys. A special shareholder meeting is scheduled for July 24, 2025 to vote on these strategic transactions. The Board of Directors has unanimously endorsed these deals, viewing them as transformative opportunities for long-term value creation.

8 months ago

#RSLS ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology ReShape Lifesciences (Nasdaq: RSLS) has secured a significant Australian patent for its Diabetes Neuromodulation technology, valid until April 2039. The technology utilizes the company's proprietary vBloc™ platform to treat Type 2 diabetes through vagus nerve modulation.The system employs targeted bioelectronic modulation of vagal nerves using implanted electrodes and an intelligent pulse generator that interfaces with external devices and glucose monitors. Preclinical studies in Zucker rats and alloxan-treated swine have demonstrated effective glycemic control. The technology is supported by 63 issued or pending patents covering areas including vagal neuromodulation, glucose regulation, artificial intelligence, and Bluetooth-enabled applications.

8 months ago

#RSLS ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Thu Jun 12th - #SOAR #RSLS #UUUU #UEC #SGMT #SERA #RGTI #QUBT #NVTS #NMAX #MGNX #KULR #EVH #DAWN #CGTL #EQX #APLD #AMPX #ALLO #AI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

1 0 0 0

9 months ago

NEWS: ( NASDAQ: #RSLS ) PRISM Mid-Day Movers: Distribution Deal and Warrant Cancellation Boost Indices

0 0 0 0

@prismmarketview.bsky.social

9 months ago

JUST IN: ( NASDAQ: #RSLS ) ReShape Lifesciences Rallies on Military Health Partnership with Recon Supply

0 0 0 0

PRISM MarketView

9 months ago

A soldier in camouflage uniform shakes hands with a doctor in a white coat in front of an American flag, symbolizing a partnership in healthcare.

Big win for veteran healthcare! #ReShapeLifesci (NASDAQ: #RSLS) teams up with Recon Supply to bring life-changing weight loss and neuro-rehab tech to VA & DoD systems nationwide. More access, more impact.
prismmarketview.com/reshape-life...

0 0 0 0

ReShape Secures Exclusive Distribution Rights to 18M Veteran Healthcare Market with Recon Supply Deal New partnership grants ReShape exclusive access to VA and DoD healthcare systems. Recon Supply to distribute STIMEL-03 and Lap-Band 2.0 FLEX. See growth potential.

9 months ago

#RSLS ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

PRISM MarketView

@prismmarketview.bsky.social

9 months ago

PRISM Mid-Day Movers: Biotech Longevity Hopes and Weight Loss Funding Drive Market Action
#KlothoNeurosciences #KLTO Soars 568% on Longevity Gene Study
#ReShapeLifesciences #RSLS Tumbles 42% After Announcing $2.6M Offering
prismmarketview.com/prism-mid-da...

0 0 0 0

ReShape Lifesciences Prices 1M Share Public Offering at $2.50 Per Share, Raising $2.6M for Weight Loss Solutions Medical device company ReShape Lifesciences prices 1M+ share offering to advance weight loss solutions. See full offering terms and planned use of proceeds.

9 months ago

#RSLS ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

9 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Tue Jun 3rd - #CIFR #RSLS #VLRS #TNGX #SEDG #PSIX #NVTS #MCTR #LTBR #LEU #KULR #KIDZ #GRYP #DNN #CGEN #CATX #BTCS #ASPI #APLD #AI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

9 months ago

Breaking News: ( NASDAQ: #RSLS ) PRISM Mid-Day Movers: Weight Loss Device Certification and Record Uranium Production Drive Market Moves

0 0 0 0

@prismmarketview.bsky.social

9 months ago

BREAKING NEWS: ( NASDAQ: #RSLS ) ReShape Lifesciences Secures Key EU and UK Certifications, Strengthening Global Market Position, Shares Surge 40%

1 0 0 0

PRISM MarketView

9 months ago

A woman in teal activewear measuring her waist with a yellow tape measure, symbolizing weight loss and fitness, representing ReShape Lifesciences®.

#RSLS just achieved a major milestone—earning full EU MDR and UKCA certifications for its entire product portfolio well ahead of deadline. 📷 This positions the company among an elite group of medtechs ready to thrive in Europe’s stricter regulatory era.
prismmarketview.com/reshape-life...

0 0 0 0

ReShape Lifesciences Beats 2027 Deadline: Gains Crucial EU MDR Certification While Others Still Wait ReShape gains early EU/UK regulatory approval for entire medical device portfolio, joining elite group of certified manufacturers. See market access implications.

9 months ago

#RSLS ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update ReShape Lifesciences (RSLS) reported Q1 2025 financial results and provided corporate updates. The company reported revenue of $1.1 million, down 42.7% year-over-year, primarily due to GLP-1 pharmaceutical competition. Key developments include: a 1-for-25 reverse stock split effective May 9, 2025; completion of a $6.0 million public offering; and progress on the pending merger with Vyome Therapeutics and asset sale to Biorad Medisys. The company secured multiple patent allowances for its Diabetes Neuromodulation technology and signed distribution agreements with Motion Informatics and Liaison Medical. Financial metrics show gross profit at $0.7 million with a 61.2% margin, and cash position of $2.6 million as of March 31, 2025.

9 months ago

#RSLS ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/RSLS/re-shape-lifes...

0 0 0 0

10 months ago

News; ( NASDAQ: #RSLS ) PRISM Mid-Day Movers: Pharma Surge and Energy Deal Drive Trading Action

0 0 0 0

10 months ago

JUST IN: ( NASDAQ: #RSLS ) RSLS announced stock split 1-25

0 0 0 0